Intellectual Property: Why is India silent, as a compromise deal on COVID-19 therapies is worked out

The fact is, Indian and South African interests have diverged; India is not in desperate need of vaccines anymore and hence does not want to …

Will Biden dare to use march-in rights?

Health advocates are asking Washington to use laws that allow patent override on drugs developed with public funds

In the midst of war, Russia hits at patents

As US-EU sanctions deepen, Moscow passes a law to allow free use of patents owned by ‘unfriendly countries’

क्यों पेटेंट के विवादों में फंस गई है मॉडर्ना की वैक्सीन

मॉडर्ना वैक्सीन को लेकर उपजा बौद्धिक संपदा विवाद एक “�…

कोवैक्सीन रॉयल्टी का दिलचस्प मामला, क्यों उठ रहे हैं सवाल

वैक्सीन की बौद्धिक संपदा स्वामित्व पर आईसीएमआर के विरो�…

‘Compromise’ on TRIPS waiver is a sellout

Tough new conditions emerge in the compromise deal to ease WTO intellectual property barriers to production of COVID-19 medical tools

क्यूबा की वैक्सीन क्रांति

इस छोटे से राष्ट्र ने 5 टीके बनाकर न सिर्फ अपनी क्षमताओं �…

Bizarre patent tussles over a COVID-19 jab

Moderna’s many intellectual property disputes over its vaccine highlight the need for a patent-free regime to fight the pandemic

COVID-19: India trips on its patent waiver proposal

New Delhi has not backed its WTO proposal to suspend intellectual property rights on COVID-19 pharma products with robust action

Viva Cuba for its vaccine revolution

Punching way above its weight, the tiny nation has developed five vaccines, and offers hope of vaccine equity across the world    

COVID-19: Has Big Pharma enabled the rise of omicron

Major drug companies do not want to share the know-how for their vaccines; uneven global vaccine access is now resulting in …

आवरण कथा: कोविड वैक्सीन से मुनाफा कमाने वाली कंपनियों के पास तैयार हैं सारे जवाब

कोविड-19 वैक्सीन को लेकर अमीर देश अपने राष्ट्रवाद पर कायम…

आवरण कथा: जेनेरिक दवाओं की तरह सस्ती क्यों नहीं है कोविड-19 वैक्सीन?

कोविड-19 वैक्सीन जेनेरिक दवाओं की तरह सस्ती क्यों नहीं हो…

Plant protection authority sets right its potato blunder

A public campaign forced it to revoke registration of PepsiCo’s potato variety, but the agency needs to reset its priorities

आवरण कथा: गरीब देशों की मुसीबत बना विकसित देशों का 'राष्ट्रवाद'

कोविड-19 वैक्सीन को लेकर विकसित देशों का रवैया बेहद आपत्त…

आवरण कथा: कोविड-19 वैक्सीन पर नियंत्रण की लड़ाई

कोविड-19 वैक्सीन पर विकसित देशों का कब्जा बरकार है। इस पि�…

आवरण कथा: कोविड-19 वैक्सीन के साथ ही सामने आया बड़ी फार्मा कंपनियों का असली चरित्र

कोविड-19 वैक्सीन को लेकर दुनिया भर में छिड़ी जंग पर डाउन ट�…

Moderna’s brazen patent grab on a COVID-19 jab

The US administration is finally putting its foot down on the appropriation of public research by drug firms  

The bizarre demand for a Banarasi paan GI

Geographical Indication tag continues to be handed out without examining the scientific basis or the integrity of such claims

The fading mirage of a TRIPS waiver

A year later, the proposal to lift WTO’s intellectual property blocks to making COVID vaccines has not inched forward

When Big Pharma has all the answers

IFPMA, the biopharma trade body, has made its claim clear: COVID-19 vaccine management should be left to these handful of companies; and all …

Katalin Karikó and the innovation issue

Rockstar scientist Kariko’s obsessive research of mRNA has prompted NYT to say she ‘helped shield the world from the coronavirus&…

Grotesque profits in the time of COVID-19

Vaccine equity goes for a toss as US recommends booster shots, while Pfizer and Moderna revenues soar by billions of dollars

Coronavirus vaccines: TRIPS waiver caught in WTO labyrinth

Little change in the position of countries opposing waiver of intellectual property rights; India-South Africa proposal being through hoops …

Coronavirus vaccines: Tech transfer is the new mantra

A tech transfer hub for mRNA vaccines is being set up in South Africa, a first for the continent; but will the pharmaceutical companies play ball?